Tilray

A federal appeals court refused to pause the Biden administration's move to consider broader rescheduling of marijuana, keeping alive a proposal to reclassify cannabis to Schedule III. Schedule III would not legalize recreational use or interstate commerce but could ease research and expand medical opportunities that would help Tilray's international medical cannabis business. Tilray reported record fiscal 2026 revenue, sharply improved cash flow and near-elimination of net debt, and management sees U.S. rescheduling as a future growth opportunity. Legal challenges and timing remain uncertain, so potential investors should view rescheduling as upside rather than a guaranteed catalyst. » Więcej na finance.yahoo.com

Tilray Brands reported record fiscal 2026 revenue of about $915 million and an 11% rise in adjusted EBITDA to $61.1 million, with adjusted net income nearly doubling to $12.2 million. The results nonetheless missed sell-side forecasts and the company recorded a GAAP net loss of $49.6 million. Management guided to modest adjusted EBITDA growth for fiscal 2027 and has reduced debt largely through dilutive debt-for-equity swaps, while cannabis now represents only 29% of sales, leaving investors hesitant to drive the stock higher. » Więcej na finance.yahoo.com

Tilray has expanded its annual cultivation capacity from 210 to about 275 tonnes, mainly through production increases in Quebec and at the EU‑GMP‑certified plant in Portugal. Quebec now supplies large volumes to sites in Portugal and Australia, is aiming for EU‑GMP certification within 12 months and has built up inventories for international markets. In Germany the Aphria RX facility is running at full capacity and the new ARX brand has been launched, strengthening Tilray’s supply infrastructure for Europe, the UK and other regulated markets. » Więcej na finanzen.net